Abstract 1871P
Background
Evidence suggests that introducing eHealth ecosystems improves the clinical management of chronic pain (CP) in breast cancer patients (BCPs). These tools contribute to overcoming established contextual, social, and individual barriers by monitoring patients' physical health and psychological well-being and early recognizing high-risk patients. Moreover, eHealth ecosystems increase patient participation in treatment decisions through specific decision aids modules, thus enabling shared decisions.
Methods
This pilot study is nested in PainRELife Project (ID:1173269). The primary endpoint was investigating patients' usability experience using an eHealth ecosystem constituted by Nu Platform joined with the PainRELife mobile application. Twenty-five female BCPs (Mage=47, SD=8.41) were enrolled and utilized the mobile application for three months. A set of self-report measures were administered at scheduled time points evaluating the following constructs: physical and mental characteristics; pain experience and intensity; pain self-efficacy; and patients’ preferences for participating in clinical decision-making and shared decision-making. The usability was evaluated by means of the Mobile Application Rating Scale (MARS).
Results
A reduction in pain intensity was observed from baseline (M=5) to 3 months (M=3.72), p<.04. The BCPs reported high values in all subscales of the MARS: engagement (M=3.31); functionality (M=4.14); aesthetics (M= 3.98); quality of the information (M=4.18); subjective quality (M=3.5); influence to change patient behaviors (M=4.05). A positive correlation was found between shared decision-making and engagement (r=.445*), quality of the information (r=.427*), and subjective quality attributed to the mobile application (r=.548**).
Conclusions
The eHealth ecosystems could be valuable aids in supporting clinicians and patients to accomplish the physical, social, and psychological challenges associated with the disease’s trajectory, also improving patients’ participation in treatment decisions allowing the implementation into clinical practice of shared decision-making models.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Applied Research Division for Cognitive and Psychological Science, European Institute of Oncology, IRCCS.
Funding
This work is supported by a grant from Regione Lombardia - “PainRELife, Sustainable and integrat-ed big data ecosystem for continuity of care and decision support for patients with pain" (ID: 1173269). The European Institute of Oncology (Istituto Europeo di Oncologia - IEO, Italy) monitors the scientific, legal, and ethical aspects of the study. Participants are recruited at IEO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05